MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

This study is testing a combination of an immune-boosting therapy (MASCT-I) with standard chemotherapy (doxorubicin and ifosfamide) as a first-line treatment for people with advanced soft tissue sarcoma — a cancer arising from tissues like muscle, fat, blood vessels, and nerves. **You may be eligible if...** - You are between 18 and 70 years old - You have confirmed advanced (unresectable or metastatic) soft tissue sarcoma of specific subtypes (e.g., leiomyosarcoma, liposarcoma, synovial sarcoma, and others) - You have not previously received systemic chemotherapy for advanced disease - You have measurable tumor(s), adequate physical function (ECOG 0-1), and expected survival over 6 months - Your blood counts and organ function are within acceptable limits **You may NOT be eligible if...** - Your sarcoma subtype is not eligible for the study - You have received prior chemotherapy or targeted therapy for advanced disease (unless your disease relapsed more than 6 months after completing adjuvant therapy) - Your blood counts or organ function do not meet the required thresholds Talk to your doctor to see if this trial is right for you.